Search

Your search keyword '"Twisk, Jos W.R."' showing total 134 results
Start Over Author "Twisk, Jos W.R." Publication Year Range Last 3 years
134 results on '"Twisk, Jos W.R."'

11. Bias in the measurement of the outcome is associated with effect sizes in randomized clinical trials on exercise therapy for chronic low back pain: a meta-epidemiological study

Author

Innocenti, Tiziano, Hayden, Jill A., Salvioli, Stefano, Giagio, Silvia, Piano, Leonardo, Cosentino, Carola, Brindisino, Fabrizio, Feller, Daniel, Ogilvie, Rachel, Gianola, Silvia, Castellini, Greta, Bargeri, Silvia, Twisk, Jos W.R., Ostelo, Raymond W., and Chiarotto, Alessandro

Published
2023
Full Text
View/download PDF

14. Patterns of Objectively Measured Sedentary Behavior and Physical Activity and Their Association with Changes in Physical and Functional Performance in Geriatric Rehabilitation Inpatients

Author

Rojer, Anna G.M., Ramsey, Keenan A., Trappenburg, Marijke C., Meskers, Carel G.M., Twisk, Jos W.R., Goonan, Rose, Marston, Celia, Kay, Jacqui, Lim, Wen Kwang, Turbić, Alisa, Island, Louis, Denehy, Linda, Parry, Selina M., Reijnierse, Esmee M., Pijnappels, Mirjam, and Maier, Andrea B.

Published
2023
Full Text
View/download PDF

17. Percutaneous coronary intervention of native coronary artery versus saphenous vein graft in patients with prior coronary artery bypass graft surgery: Rationale and design of the multicenter, randomized PROCTOR trial

Author

de Winter, Ruben W., Walsh, Simon J., Hanratty, Colm G., Spratt, James C., Sprengers, Ralf W., Twisk, Jos W.R., Vegting, Iris, Schumacher, Stefan P., Bom, Michiel J., Hoek, Roel, Verouden, Niels J., Delewi, Ronak, Nap, Alexander, and Knaapen, Paul

Published
2023
Full Text
View/download PDF

19. Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [15O]H2O PET Imaging

Author

Hoek, Roel, primary, van Diemen, Pepijn A., additional, Raijmakers, Pieter G., additional, Driessen, Roel S., additional, Somsen, Yvemarie B.O., additional, de Winter, Ruben W., additional, Jukema, Ruurt A., additional, Twisk, Jos W.R., additional, Robbers, Lourens F.H.J., additional, van der Harst, Pim, additional, Saraste, Antti, additional, Lubberink, Mark, additional, Sörensen, Jens, additional, Knaapen, Paul, additional, Knuuti, Juhani, additional, and Danad, Ibrahim, additional

Published
2024
Full Text
View/download PDF

20. Neuroinflammation is associated with Alzheimer’s disease co-pathology in dementia with Lewy bodies

Author

Wetering, Janna van, primary, Geut, Hanne, additional, Bol, John J., additional, Galis, Yvon, additional, Timmermans, Evelien, additional, Twisk, Jos W.R., additional, Hepp, Dagmar H., additional, Morella, Martino L., additional, Pihlstrom, Lasse, additional, Lemstra, Afina W., additional, Rozemuller, Annemieke J.M., additional, Jonkman, Laura E., additional, and van de Berg, Wilma D.J., additional

Published
2024
Full Text
View/download PDF

30. The development of fatigue after treatment for pediatric brain tumors does not differ between tumor locations

Author

P&O Programma's, Flex en UMCU-breed, Endocrinologie patientenzorg, Brain, Cancer, Child Health, Highfield Research Group, Speerpunt, Zorg en O&O, Irestorm, Elin, Schouten-van Meeteren, Antoinette Y.N., van Gorp, Marloes, Twisk, Jos W.R., van Santen, Hanneke M., Partanen, Marita, Grootenhuis, Martha A., van Litsenburg, Raphaele R.L., P&O Programma's, Flex en UMCU-breed, Endocrinologie patientenzorg, Brain, Cancer, Child Health, Highfield Research Group, Speerpunt, Zorg en O&O, Irestorm, Elin, Schouten-van Meeteren, Antoinette Y.N., van Gorp, Marloes, Twisk, Jos W.R., van Santen, Hanneke M., Partanen, Marita, Grootenhuis, Martha A., and van Litsenburg, Raphaele R.L.

Published
2024

31. The immunological landscape of peripheral blood in glioblastoma patients and immunological consequences of age and dexamethasone treatment

Author

Sub AI Technology for Life, AI Technology for Life, Dusoswa, Sophie A., Verhoeff, Jan, van Asten, Saskia, Lübbers, Joyce, van den Braber, Marlous, Peters, Sophie, Abeln, Sanne, Crommentuijn, Matheus H.W., Wesseling, Pieter, Vandertop, William Peter, Twisk, Jos W.R., Würdinger, Thomas, Noske, David, van Kooyk, Yvette, Garcia-Vallejo, Juan J., Sub AI Technology for Life, AI Technology for Life, Dusoswa, Sophie A., Verhoeff, Jan, van Asten, Saskia, Lübbers, Joyce, van den Braber, Marlous, Peters, Sophie, Abeln, Sanne, Crommentuijn, Matheus H.W., Wesseling, Pieter, Vandertop, William Peter, Twisk, Jos W.R., Würdinger, Thomas, Noske, David, van Kooyk, Yvette, and Garcia-Vallejo, Juan J.

Published
2024

32. Hemodynamic Insights into Combined Fractional Flow Reserve and Instantaneous Wave-Free Ratio Assessment Through Quantitative [15O]H2O PET Myocardial Perfusion Imaging

Author

de Winter, Ruben W., primary, van Diemen, Pepijn A., additional, Schumacher, Stefan P., additional, Jukema, Ruurt A., additional, Somsen, Yvemarie B.O., additional, Hoek, Roel, additional, van Rossum, Albert C., additional, Twisk, Jos W.R., additional, de Waard, Guus A., additional, Nap, Alexander, additional, Raijmakers, Pieter G., additional, Driessen, Roel S., additional, Knaapen, Paul, additional, and Danad, Ibrahim, additional

Published
2024
Full Text
View/download PDF

35. Methotrexate safety and efficacy in combination therapies in patients with early rheumatoid arthritis: a post‐hoc analysis of a randomized controlled trial (NORD‐STAR)

Author

Lend, Kristina, primary, Koopman, Frieda A, additional, Lampa, Jon, additional, Jansen, Gerrit, additional, L, Merete Hetland, additional, Uhlig, Till, additional, Nordström, Dan, additional, Nurmohamed, Michael, additional, Gudbjornsson, Bjorn, additional, Rudin, Anna, additional, Østergaard, Mikkel, additional, Heiberg, Marte S, additional, Sokka‐Isler, Tuulikki, additional, Hørslev‐Petersen, Kim, additional, Haavardsholm, Espen A, additional, Grondal, Gerdur, additional, Twisk, Jos W.R., additional, and van Vollenhoven, Ronald, additional

Published
2023
Full Text
View/download PDF

37. Prognostic Value of Modified Coronary Flow Capacity Derived From [ 15 O]H 2 O Positron Emission Tomography Perfusion Imaging

Author

de Winter, Ruben W., primary, Jukema, Ruurt A., additional, van Diemen, Pepijn A., additional, Schumacher, Stefan P., additional, Somsen, Yvemarie B.O., additional, van de Hoef, Tim P., additional, van Rossum, Albert C., additional, Twisk, Jos W.R., additional, Maaniitty, Teemu, additional, Knuuti, Juhani, additional, Saraste, Antti, additional, Nap, Alexander, additional, Raijmakers, Pieter G., additional, Danad, Ibrahim, additional, and Knaapen, Paul, additional

Published
2023
Full Text
View/download PDF

39. Physical Resilience in Daily Functioning Among Acutely Ill Hospitalized Older Adults: The Hospital-ADL Study

Author

Reichardt, Lucienne A., Aarden, Jesse, van Seben, Rosanne, van der Schaaf, Marike, van der Esch, Martin, Engelbert, Raoul H.H., Twisk, Jos W.R., Bosch, Jos A., Kuper, Ingeborg, de Jonghe, Annemarieke, Leguit-Elberse, Maike, Kamper, Ad, Posthuma, Nynke, Brendel, Nienke, Wold, Johan, Kolk, Daisy, Melis, René J.F., MacNeil-Vroomen, Janet L., and Buurman, Bianca M.

Published
2022
Full Text
View/download PDF

41. Supplementary table S1 from Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma

Author

Meel, Michaël H., primary, de Gooijer, Mark C., primary, Metselaar, Dennis S., primary, Sewing, A. Charlotte P., primary, Zwaan, Kenn, primary, Waranecki, Piotr, primary, Breur, Marjolein, primary, Buil, Levi C.M., primary, Lagerweij, Tonny, primary, Wedekind, Laurine E., primary, Twisk, Jos W.R., primary, Koster, Jan, primary, Hashizume, Rintaro, primary, Raabe, Eric H., primary, Montero Carcaboso, Ángel, primary, Bugiani, Marianna, primary, Phoenix, Timothy N., primary, van Tellingen, Olaf, primary, van Vuurden, Dannis G., primary, Kaspers, Gertjan J.L., primary, and Hulleman, Esther, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Data Legends from Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma

Author

Meel, Michaël H., primary, de Gooijer, Mark C., primary, Metselaar, Dennis S., primary, Sewing, A. Charlotte P., primary, Zwaan, Kenn, primary, Waranecki, Piotr, primary, Breur, Marjolein, primary, Buil, Levi C.M., primary, Lagerweij, Tonny, primary, Wedekind, Laurine E., primary, Twisk, Jos W.R., primary, Koster, Jan, primary, Hashizume, Rintaro, primary, Raabe, Eric H., primary, Montero Carcaboso, Ángel, primary, Bugiani, Marianna, primary, Phoenix, Timothy N., primary, van Tellingen, Olaf, primary, van Vuurden, Dannis G., primary, Kaspers, Gertjan J.L., primary, and Hulleman, Esther, primary

Published
2023
Full Text
View/download PDF

43. Figure S2 from MELK Inhibition in Diffuse Intrinsic Pontine Glioma

Author

Meel, Michaël H., primary, de Gooijer, Mark C., primary, Guillén Navarro, Miriam, primary, Waranecki, Piotr, primary, Breur, Marjolein, primary, Buil, Levi C.M., primary, Wedekind, Laurine E., primary, Twisk, Jos W.R., primary, Koster, Jan, primary, Hashizume, Rintaro, primary, Raabe, Eric H., primary, Montero Carcaboso, Angel, primary, Bugiani, Marianna, primary, van Tellingen, Olaf, primary, van Vuurden, Dannis G., primary, Kaspers, Gertjan J.L., primary, and Hulleman, Esther, primary

Published
2023
Full Text
View/download PDF

44. Supplementary figures from Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma

Author

Meel, Michaël H., primary, de Gooijer, Mark C., primary, Metselaar, Dennis S., primary, Sewing, A. Charlotte P., primary, Zwaan, Kenn, primary, Waranecki, Piotr, primary, Breur, Marjolein, primary, Buil, Levi C.M., primary, Lagerweij, Tonny, primary, Wedekind, Laurine E., primary, Twisk, Jos W.R., primary, Koster, Jan, primary, Hashizume, Rintaro, primary, Raabe, Eric H., primary, Montero Carcaboso, Ángel, primary, Bugiani, Marianna, primary, Phoenix, Timothy N., primary, van Tellingen, Olaf, primary, van Vuurden, Dannis G., primary, Kaspers, Gertjan J.L., primary, and Hulleman, Esther, primary

Published
2023
Full Text
View/download PDF

45. Table S2 from MELK Inhibition in Diffuse Intrinsic Pontine Glioma

Author

Meel, Michaël H., primary, de Gooijer, Mark C., primary, Guillén Navarro, Miriam, primary, Waranecki, Piotr, primary, Breur, Marjolein, primary, Buil, Levi C.M., primary, Wedekind, Laurine E., primary, Twisk, Jos W.R., primary, Koster, Jan, primary, Hashizume, Rintaro, primary, Raabe, Eric H., primary, Montero Carcaboso, Angel, primary, Bugiani, Marianna, primary, van Tellingen, Olaf, primary, van Vuurden, Dannis G., primary, Kaspers, Gertjan J.L., primary, and Hulleman, Esther, primary

Published
2023
Full Text
View/download PDF

46. Efficacy and moderators of short-term psychodynamic psychotherapy for depression: A systematic review and meta-analysis of individual participant data

Author

Wienicke, Frederik J., primary, Beutel, Manfred E., additional, Zwerenz, Rüdiger, additional, Brähler, Elmar, additional, Fonagy, Peter, additional, Luyten, Patrick, additional, Constantinou, Matthew, additional, Barber, Jacques P., additional, McCarthy, Kevin S., additional, Solomonov, Nili, additional, Cooper, Peter J., additional, De Pascalis, Leonardo, additional, Johansson, Robert, additional, Andersson, Gerhard, additional, Lemma, Alessandra, additional, Town, Joel M., additional, Abbass, Allan A., additional, Ajilchi, Bita, additional, Gibbons, Mary Beth Connolly, additional, López-Rodríguez, Jaime, additional, Villamil-Salcedo, Valerio, additional, Maina, Giuseppe, additional, Rosso, Gianluca, additional, Twisk, Jos W.R., additional, Burk, William J., additional, Spijker, Jan, additional, Cuijpers, Pim, additional, and Driessen, Ellen, additional

Published
2023
Full Text
View/download PDF

47. Randomized controlled trial on the effect of 1-hour infusion of vincristine versus push injection on neuropathy in children with cancer (final analysis)

Author

Uittenboogaard, Aniek, van den Berg, Marleen H., Abbink, Floor C.H., Twisk, Jos W.R., van der Sluis, Inge M., van den Bos, Cor, van den Heuvel-Eibrink, Marry M., Segers, Heidi, Chantrain, Christophe, van der Werff ten Bosch, Jutte, Willems, Leen, Kaspers, Gertjan J.L., van de Velde, Mirjam Esther, Uittenboogaard, Aniek, van den Berg, Marleen H., Abbink, Floor C.H., Twisk, Jos W.R., van der Sluis, Inge M., van den Bos, Cor, van den Heuvel-Eibrink, Marry M., Segers, Heidi, Chantrain, Christophe, van der Werff ten Bosch, Jutte, Willems, Leen, Kaspers, Gertjan J.L., and van de Velde, Mirjam Esther

Abstract

Introduction: Vincristine is an integral component of treatment for children with cancer. Its main dose-limiting side effect is vincristine-induced peripheral neuropathy (VIPN). The VINCA trial was a randomized controlled trial that explored the effect of 1-hour infusion compared with push injection of vincristine on the development of VIPN in children with cancer. The short-term outcomes (median follow-up 9 months) showed that there was no difference in VIPN between the randomization groups. However, 1-hour infusion was less toxic in children who also received azoles. We now report the results of the final analyses (median follow-up 20 months), which includes treatment outcome as a secondary objective (follow-up 3 years). Methods: VIPN was measured 1–7 times per participant using the Common Terminology Criteria for Adverse Events (CTCAE) and the pediatric-modified total neuropathy score. Poisson mixed model and logistic generalized estimating equation analysis for repeated measures were performed.Results: Forty-five participants per randomization group were included. There was no significant effect of 1-hour infusion compared with push injection on VIPN. In participants receiving concurrent azoles, the total CTCAE score was significantly lower in the one-hour group (rate ratio 0.52, 95% confidence interval 0.33–0.80, p = 0.003). Four patients in the one-hour group and one patient in the push group relapsed. Two patients in the one-hour group died. Conclusion:1-hour infusion of vincristine is not protective against VIPN. However, in patients receiving concurrent azoles, 1-hour infusion may be less toxic. The difference in treatment outcome is most likely the result of differences in risk profile.

Published
2023

48. Association between prehospital end-tidal carbon dioxide levels and mortality in patients with suspected severe traumatic brain injury

Author

Bossers, Sebastiaan M., Mansvelder, Floor, Loer, Stephan A., Boer, Christa, Bloemers, Frank W., Van Lieshout, Esther M.M., Den Hartog, Dennis, Hoogerwerf, Nico, van der Naalt, Joukje, Absalom, Anthony R., Schwarte, Lothar A., Twisk, Jos W.R., Schober, Patrick, Bossers, Sebastiaan M., Mansvelder, Floor, Loer, Stephan A., Boer, Christa, Bloemers, Frank W., Van Lieshout, Esther M.M., Den Hartog, Dennis, Hoogerwerf, Nico, van der Naalt, Joukje, Absalom, Anthony R., Schwarte, Lothar A., Twisk, Jos W.R., and Schober, Patrick

Abstract

Purpose: Severe traumatic brain injury is a leading cause of mortality and morbidity, and these patients are frequently intubated in the prehospital setting. Cerebral perfusion and intracranial pressure are influenced by the arterial partial pressure of CO2 and derangements might induce further brain damage. We investigated which lower and upper limits of prehospital end-tidal CO2 levels are associated with increased mortality in patients with severe traumatic brain injury. Methods: The BRAIN-PROTECT study is an observational multicenter study. Patients with severe traumatic brain injury, treated by Dutch Helicopter Emergency Medical Services between February 2012 and December 2017, were included. Follow-up continued for 1 year after inclusion. End-tidal CO2 levels were measured during prehospital care and their association with 30-day mortality was analyzed with multivariable logistic regression. Results: A total of 1776 patients were eligible for analysis. An L-shaped association between end-tidal CO2 levels and 30-day mortality was observed (p = 0.01), with a sharp increase in mortality with values below 35 mmHg. End-tidal CO2 values between 35 and 45 mmHg were associated with better survival rates compared to < 35 mmHg. No association between hypercapnia and mortality was observed. The odds ratio for the association between hypocapnia (< 35 mmHg) and mortality was 1.89 (95% CI 1.53–2.34, p < 0.001) and for hypercapnia (≥ 45 mmHg) 0.83 (0.62–1.11, p = 0.212). Conclusion: A safe zone of 35–45 mmHg for end-tidal CO2 guidance seems reasonable during prehospital care. Particularly, end-tidal partial pressures of less than 35 mmHg were associated with a significantly increased mortality.

Published
2023

49. The influence of apical periodontitis on circulatory inflammatory mediators in peripheral blood: A prospective case–control study

Author

UMC Utrecht Holding, CDL Unit Externe Business/ ARCADIA, CDL Arcadia, Georgiou, Athina Christina, Twisk, Jos W.R., Crielaard, Wim, Ouwerling, Peter, Schoneveld, Arjan H., van der Waal, Suzette Veronica, UMC Utrecht Holding, CDL Unit Externe Business/ ARCADIA, CDL Arcadia, Georgiou, Athina Christina, Twisk, Jos W.R., Crielaard, Wim, Ouwerling, Peter, Schoneveld, Arjan H., and van der Waal, Suzette Veronica

Published
2023

50. Effectiveness of psychosomatic therapy for patients with persistent somatic symptoms:Results from the CORPUS randomised controlled trial in primary care

Author

Wortman, Margreet S.H., van der Wouden, Johannes C., Twisk, Jos W.R., Visser, Bart, Assendelft, Willem J.J., van der Horst, Henriëtte E., Olde Hartman, Tim C., General practice, APH - Aging & Later Life, APH - Quality of Care, Epidemiology and Data Science, APH - Health Behaviors & Chronic Diseases, APH - Methodology, APH - Mental Health, Lectoraat Oefentherapie, and Urban Vitality

Subjects
Psychiatry and Mental health, Clinical Psychology, All institutes and research themes of the Radboud University Medical Center, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]
Abstract

ObjectiveTo evaluate the effectiveness of psychosomatic therapy versus care as usual in primary care for patients with persistent somatic symptoms (PSS).MethodsWe conducted a pragmatic, two-armed, randomised controlled trial among primary care patients with PSS in the Netherlands that included 39 general practices and 34 psychosomatic therapists. The intervention, psychosomatic therapy, consisted of 6–12 sessions delivered by specialised exercise- and physiotherapists. Primary outcome measure: patient's level of functioning. Secondary outcomes: severity of physical and psychosocial symptoms, health-related quality of life, health-related anxiety, illness behaviour and number of GP contacts.ResultsCompared to usual care (n = 85), the intervention group (n = 84) showed no improvement in patient's level of functioning (mean difference − 0.50 [95% CI -1.10 to 0.10]; p = .10), and improvement in health-related anxiety (mean difference − 1.93 [95% CI -3.81 to −0.04]; p = .045), over 12 months. At 5-month follow-up, we found improvement in physical functioning, somatisation, and health-related anxiety. The 12-month follow-up revealed no therapy effects. Subgroup analyses showed an overall effect in patient's level of functioning for the group with moderate PSS (mean difference − 0.91 [95% CI -1.78 to −0.03]; p = .042). In the year after the end of therapy, the number of GP contacts did not differ significantly between the two groups.ConclusionWe only found effects on some secondary outcome measures, and on our primary outcome measure especially in patients with moderate PSS, the psychosomatic therapy appears promising for further study.Trial registration: the trial is registered in the Netherlands Trial Registry, https://trialsearch.who.int/Trial2.aspx?TrialID=NTR7356 under ID NTR7356.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results